Medtronic Gets FDA Approval Of Enlite Sensor For iPro®2 Professional Continuous Glucose Monitoring System

Medtronic plc MDT disclosed that the FDA has given its approval of the Enlite sensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system. This is a market-leading CGM system, which allows healthcare providers to get a clear picture of glucose control for the diabetes patients they treat.

The medical device maker said that the Enlite sensor is a disposable glucose sensor, which could be worn up to six days providing better comfort to the patients.

Medtronic's VP and GM for Non-Intensive Diabetes Therapies, Laura Stoltenberg, said, "We fundamentally believe that to improve outcomes for people with diabetes, physicians need advanced insights to optimize therapy and people with diabetes need to understand the context behind glucose fluctuations to drive behavior change."

The company indicated that the iPro2 Professional CGM system records a patient's glucose levels 24 hours a day for a maximum of six days. The iPro2 system offers physicians with insights into the nutrition plan, medication regimen and daily activities that affect glucose levels of people with diabetes.

On Thursday, the stock shed $0.08, or 0.09 percent, to $86.95.